Private Advisor Group LLC Has $493,000 Holdings in Haleon plc (NYSE:HLN)

Private Advisor Group LLC raised its holdings in shares of Haleon plc (NYSE:HLN) by 7.2% in the fourth quarter, Holdings Channel reports. The institutional investor owned 51,724 shares of the company’s stock after buying an additional 3,490 shares during the quarter. Private Advisor Group LLC’s holdings in Haleon were worth $493,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently modified their holdings of the company. FMR LLC raised its stake in shares of Haleon by 5.8% in the third quarter. FMR LLC now owns 104,918,269 shares of the company’s stock valued at $1,110,035,000 after purchasing an additional 5,768,117 shares in the last quarter. Wellington Management Group LLP raised its stake in shares of Haleon by 49.9% in the third quarter. Wellington Management Group LLP now owns 9,152,490 shares of the company’s stock valued at $96,833,000 after purchasing an additional 3,046,841 shares in the last quarter. JPMorgan Chase & Co. raised its stake in Haleon by 25.3% during the third quarter. JPMorgan Chase & Co. now owns 5,084,202 shares of the company’s stock worth $53,791,000 after acquiring an additional 1,026,939 shares in the last quarter. Natixis Advisors LLC raised its stake in Haleon by 142.5% during the third quarter. Natixis Advisors LLC now owns 1,473,767 shares of the company’s stock worth $15,593,000 after acquiring an additional 866,070 shares in the last quarter. Finally, Van ECK Associates Corp increased its stake in shares of Haleon by 13.5% in the fourth quarter. Van ECK Associates Corp now owns 3,509,400 shares of the company’s stock valued at $33,480,000 after buying an additional 418,609 shares in the last quarter. 6.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on HLN. Sanford C. Bernstein lowered Haleon from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 8th. Morgan Stanley lowered Haleon from an “overweight” rating to an “equal weight” rating in a research report on Friday, January 10th. Three equities research analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $10.95.

Haleon Price Performance

Haleon stock opened at $10.59 on Tuesday. Haleon plc has a 1 year low of $7.89 and a 1 year high of $10.80. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. The firm has a market capitalization of $47.94 billion, a P/E ratio of 31.15, a PEG ratio of 2.82 and a beta of 0.28. The business has a 50-day moving average of $9.59 and a 200-day moving average of $9.84.

Haleon (NYSE:HLN) last released its quarterly earnings data on Thursday, February 27th. The company reported $0.05 earnings per share for the quarter. Haleon had a return on equity of 14.76% and a net margin of 10.85%. The business had revenue of $3.54 billion for the quarter, compared to analysts’ expectations of $3.38 billion. On average, equities analysts anticipate that Haleon plc will post 0.43 EPS for the current year.

Haleon Increases Dividend

The company also recently announced a — dividend, which will be paid on Thursday, June 5th. Shareholders of record on Friday, April 25th will be paid a $0.1166 dividend. This is a boost from Haleon’s previous — dividend of $0.05. The ex-dividend date is Friday, April 25th. This represents a yield of 1.6%. Haleon’s payout ratio is presently 58.97%.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.